Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 1/20 | 0.52 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.52 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 4/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | MGLL | Q99685 | 1/20 | 0.35 |
| ▸ | GBA1 | P04062 | 2/20 | 0.35 |
| ▸ | MLNR | O43193 | 1/20 | 0.33 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.33 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.33 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13220 | 0.98 | ADRA2C (0.56) | CHRM5ADRA2CHSD11B1HRH3NAMPT | |
| SCHEMBL18682635 | 0.86 | CHRM5 (0.62) | CHRM5ADRA2CHSD11B1HRH3ACHE | |
| SCHEMBL12618 | 0.84 | CHRM5 (0.67) | CHRM5ADRA2CHRH3ACHEGBA1 | |
| SCHEMBL8261146 | 0.82 | ACHE (0.55) | CHRM5ADRA2CHSD11B1HRH3NAMPT | |
| SCHEMBL3950204 | 0.82 | NAMPT (0.38) | CHRM5ADRA2CHSD11B1NAMPTMGLL | |
| SCHEMBL7226560 | 0.82 | NAMPT (0.36) | CHRM5ADRA2CHSD11B1NAMPTACHE | |
| SCHEMBL18713019 | 0.82 | NAMPT (0.40) | CHRM5ADRA2CHSD11B1HRH3NAMPT | |
| SCHEMBL5012467 | 0.82 | NAMPT (0.36) | CHRM5ADRA2CHSD11B1NAMPTACHE | |
| SCHEMBL10092855 | 0.82 | GBA1 (0.36) | CHRM5ADRA2CHSD11B1NAMPTMGLL | |
| SCHEMBL18873650 | 0.82 | NAMPT (0.38) | CHRM5ADRA2CHSD11B1NAMPTACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120238545-A1 | TRICYCLIC PYRAZOL AMINE DERIVATIVES | MERCK SERONO SA (CH) | 2012-09-20 | — | — | US | disclosed |
| WO-2011058149-A1 | TRICYCLIC PYRAZOL AMINE DERIVATIVES | MERCK SERONO S.A. (CH) | 2011-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238545-A1 | TRICYCLIC PYRAZOL AMINE DERIVATIVES | PI4KB, MTOR, PI4KA | CHRM5 4062/4885ADRA2C 3042/4885HSD11B1 1944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.